6de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: Ffom laboratory bench to bedside [J]. Recent Results Cancer Res, 2007(169) :53-73 .
8Warschkow R, Tarantino I, Lange J, et al. Does hyperthermic in- traoperative chemotherapy lead to improved outcomes in patients with ovarian cancer.'? A single center cohort study in 111 consecu-tive patients [ J ]. Patient Saf Surg, 2012,6 ( 1 ) : 12.
9Spiliotis J, Vaxevanidou A, Sergouniotis F, et al. The role of cy- toreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a pro- spective study[J]. J Buon, 2011,16(1 ) :74-79.
10Bakrin N, Cotte E, Golfier F, et at. Cytoreductive surgery and hy- perthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospec- tive study of 246 patients [ J]. Ann Surg Oncol, 2012,19 (13) : 4052-4058.
3Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer [ J ]. Cancer Treat Rep, 1978,62 : 1-11.
4Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection[ J]. Ann Intern Med, 1982,97:845-851.
5Markman M, Howell SB, Lucas WE, et al. Combination intraperitoneal chemotherapy with cisplatin, cytarzbine, and doxombicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity [ J ]. J Clin Oncol, 1984,2 : 1321-1326.
6Petignat P, duBois A, Bruchim I, et al. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovariancancer [ J ] ? Critical Reviews in Oncology/Hematology ,2007,62 : 137-147.
7Hofstra LS,de Vries EG, Mulder NH, et al. Intraperitoneal chemotherapy in ovarian cancer [ J ]. Cancer Treat Rev, 2000,26:133-143.
8Markman M, Reichman B, Hakes T, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer[J]. Gynccol Oncol, 1993,50 : 100-104.
9Speyer JL, Sorich J. Intraperitoneal earboplatin : rationale and experience [ J ]. Semin Oncol, 1992,19 : 107-113.
10Kuh HJ, Jang SH, Wientjes MG, et al. Determinants of paclitaxel penetration and accumulation in human solid tumor [ J ]. J Pharmacol Exp Ther, 1999,290 : 871-180.
